ArticleBMC cancer2019
The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases.
Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06168292 (Intraductal Radiofrequency Thermoablation and Radiotherapy Combined Treatment for Extrahepatic Cholangiocarcinoma), which is not on this map. Cited by 51 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Intraductal Radiofrequency Thermoablation and Radiotherapy Combined Treatment for Extrahepatic Cholangiocarcinoma: A Prospective, Single-arm, Multicenter Study
Who cites it
51 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Isolated para-aortic lymph node recurrence from colorectal cancer treated by radiotherapy: a systematic review and meta-analysis.Scientific reports · 2026Pooled it
- Comprehensive analysis of Japanese nationwide cohort data of particle beam therapy for pulmonary, liver and lymph node oligometastases: particle beam therapy versus high-precision X-ray radiotherapy.Journal of radiation research · 2023Pooled it
- Microwave Ablation, Radiofrequency Ablation, Irreversible Electroporation, and Stereotactic Ablative Body Radiotherapy for Intermediate Size (3-5 cm) Unresectable Colorectal Liver Metastases: a Systematic Review and Meta-analysis.Current oncology reports · 2022Pooled it
- Stereotactic body radiotherapy in patients with bone oligometastases from breast cancer - results from a European multicenter cohort study.Clinical and translational radiation oncology · 2026Article
- Article
- Predictive factors of response in lung metastases treated by sbrt from colon rectal cancer.Clinical & experimental metastasis · 2026Article
- Towards a personalized utilization of stereotactic body radiotherapy for the management of liver metastases in solid tumors.Cancer metastasis reviews · 2025Review
- Prognostic factors and risk stratification for survival in oligometastatic colorectal cancer treated with stereotactic body radiotherapy.Radiation oncology journal · 2025Article
- Combination of Irreversible Electroporation andCancers · 2025Review
- Effects of maximum dose on local control after stereotactic body radiotherapy for oligometastatic tumors of colorectal cancer.PloS one · 2025Article
- Metastasis-directed stereotactic radiotherapy in patients with breast cancer: results of an international multicenter cohort study.Clinical & experimental metastasis · 2024Article
- Stereotactic radiotherapy for liver oligometastases: a pooled analysis following the estro/eortc consensus recommendations.Clinical & experimental metastasis · 2024Article
- Insurance Denials and Patient Treatment in a Large Academic Radiation Oncology Center.JAMA network open · 2024Article
- Stereotactic body radiotherapy takes on Lung Oligometastases: Latest breakthroughs.Precision radiation oncology · 2024Review
- Article
- Review
- Real-world effectiveness and safety of stereotactic body radiotherapy for liver metastases with different respiratory motion management techniques.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2023Article
- Colorectal Pulmonary Metastases: Pulmonary Metastasectomy or Stereotactic Radiotherapy?Cancers · 2023Article
- Local Control Following Stereotactic Body Radiation Therapy for Liver Oligometastases: Lessons from a Quarter Century.Current oncology (Toronto, Ont.) · 2023Review
- Role of palliative SBRT in barcelona clinic liver cancer-stage C hepatocellular carcinoma patients.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2023Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this analysis was to model the effect of local control (LC) on overall survival (OS) in patients treated with stereotactic body radiotherapy (SBRT) for liver or lung metastases from colorectal cancer.
methodsThe analysis is based on pooled data from two retrospective SBRT databases for pulmonary and hepatic metastases from 27 centers from Germany and Switzerland. Only patients with metastases from colorectal cancer were considered to avoid histology as a confounding factor. An illness-death model was employed to model the relationship between LC and OS.
resultsThree hundred eighty-eight patients with 500 metastatic lesions (lung n = 209, liver n = 291) were included and analyzed. Median follow-up time for local recurrence assessment was 12.1 months. Ninety-nine patients with 112 lesions experienced local failure. Seventy-one of these patients died after local failure. Median survival time was 27.9 months in all patients and 25.4 months versus 30.6 months in patients with and without local failure after SBRT. The baseline risk of death after local failure exceeds the baseline risk of death without local failure at 10 months indicating better survival with LC.
conclusionIn CRC patients with lung or liver metastases, our findings suggest improved long-term OS by achieving metastatic disease control using SBRT in patients with a projected OS estimate of > 12 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.